Symposium hosted by Guillermo Garcia-Manero, M.D. and Eric Winer, M.D.
Academics and industry professionals will gather virtually on September 22, 2023
LEXINGTON, Mass., Sept. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced the 2nd Symposium on IRAK4 in Cancer taking place virtually on September 22, 9:00am-1:00pm ET.
Hosted by Dr. Guillermo Garcia-Manero and Dr. Eric Winer, this symposium will focus on IRAK4, a key protein in the innate immune response and an emerging target in the treatment of hematologic malignancies and solid tumors. Experts across academia and industry will discuss IRAK4's biological and immunological roles as well as the promising role of targeting IRAK4 in cancer therapeutics.
"Following the success of last year's symposium on IRAK4 in cancer, Curis is pleased to continue its sponsorship of the Annual IRAK4 Symposium," said James Dentzer, President, and Chief Executive Officer of Curis. "As a leader in IRAK4 inhibition in oncology with emavusertib, we are honored to provide a forum for discussing the biology of the IRAK4 pathway and IRAK4 inhibition in the research and development of therapies to benefit patients living with cancer."
- Guillermo Garcia-Manero, M.D. - Symposium Co-Chair - Professor, Department of Leukemia; Chief, Section of Myelodysplastic Syndromes and Deputy Chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- Eric Winer, M.D. – Symposium Co-Chair – Clinical Director, Adult Leukemia Institute Physician, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School
Joining our hosts will be the following speakers and participants:
- Omar Abdel-Wahab, M.D. - Edward P. Evans Chair in MDS, Director, Memorial Sloan Kettering Cancer Center (MSK) for Hematologic Malignancies; Member, Human Oncology and Pathogenesis Program & Leukemia Service
- Claudio Cerchione, M.D., Ph.D. - Hematologist, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
- Bentley Doonan, M.D., M.S. - Assistant Professor, Division of Hematology & Oncology, University of Florida College of Medicine
- Matthew Galsky, M.D. - Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer, Associate Director for Translational Research, Tisch Cancer institute
- Christian Grommes, M.D. – Associate Professor of Neurology, Weill Cornell Medical College; Assistant Professor of Neuroscience, Brain and Mind Research Institute, Weill Cornell Medical College; Neuro-oncologist, Memorial Sloan-Kettering Cancer Center
- Kian-Huat Lim, M.D., Ph.D. - Associate Professor, Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis
- Daniel Starczynowski, Ph.D. – Institute Associate Director for Basic Science Research, University of Cincinnati Cancer Center; Co-Chief Scientific Officer, Innovations Ventures; Katherine Stewart Waters Endowed Chair of Hematologic Malignancies, Professor in Pediatrics, Co-Leader, Hematologic Malignancies Program, Cincinnati Children's Hospital
- Richard Stone, M.D. – Chief of Staff, Dana-Farber Cancer Institute; Director of Translational Research, Adult Acute Leukemia Program, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School
- Amit Verma, M.B.B.S. – Professor, Department of Oncology (Medical Oncology), Department of Medicine (Oncology & Hematology), and Department of Developmental & Molecular Biology, Albert Einstein College of Medicine; Director, Division of Hemato-Oncology, Montefiore Department of Oncology; Associate Director, Translational Science, Montefiore Einstein Cancer Center; Co-Director, Montefiore Einstein Blood Cancer Institute
The virtual event will address topics including the biology of the IRAK4 pathway and the potential of IRAK4 inhibition in both hematologic malignancies and solid tumors. Presentations and a panel discussion will address IRAK4 biology and clinical experience with IRAK4 inhibition, the potential to overcome treatment resistance, biomarkers, and next steps in the field. To learn more about this free-to-attend symposium and register, please visit https://cvent.me/YWvRDD
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies, both as a monotherapy and in combination with the BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia study in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
SOURCE Curis, Inc.